NCT04343456

Salvage Surgery for Patients With Metastatic GIST With Rego

Analysis of Benefit From Salvage Surgery for Highly Selected Patients With Metastatic Gastrointestinal Stromal Tumors Receiving Regorafenib Facing Local Progression

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 41 (actual)
• Sponsor: Chang Gung Memorial Hospital · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Accepted

Summary

Some researches have shown surgery may acquire progression-free (PFS) benefit for selected patients with metastatic gastrointestinal stromal tumor (GIST) who received first-line imatinib and second-line sunitinib. However, impact of salvage surgery on pre-treated GIST patients receiving third-line regorafenib facing progression is not yet reported. Investigators retrospectively reviewed patients with regorafenib treatment with salvage surgery.

Detailed description

Between 2014 and 2019, 41 metastatic GIST patients received regorafenib therapy. 35 out of 41 metastatic GIST patients who were on regorafenib therapy facing progression and 15 experienced local progression underwent salvage surgery. Thirty-five of 41 (85.4 %) pre-treated GIST patients receiving regorafenib who experienced disease progression after a median follow-up of 12.4 months of regorafenib use. 15 out of 35 (42.9%) metastatic GIST patients receiving regorafenib facing progression underwent salvage surgery.

Conditions

• Gastrointestinal Stromal Tumors
• Metastasis
• Disease Progression

Interventions

Type	Name	Description
PROCEDURE	Salvage surgery with massive debulking	For patients with regorafenib treatment and facing local progression, we remove the tumor with progression and achieve cytoreduction.

Timeline

• Start date: 2014-01-01
• Primary completion: 2019-12-31
• Completion: 2020-02-28
• First posted: 2020-04-13
• Last updated: 2020-04-14

Locations

1 site across 1 country: Taiwan